Clinical Trials Browser

Phase 2 × Active not recruiting × 2-Propanol × Clear all

NCT04203316 2026-01-09

Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation

Phase 2 Active not recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03825796 2023-09-28

CPX-351 Plus Enasidenib for Relapsed AML

Phase 2 Active not recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute